
Opinion|Videos|April 4, 2025
Evaluating the Safety of Topical JAK Inhibitors in the Pediatric Population: Insights into Systemic Risks and Adverse Effects
Author(s)Aaron S. Farberg, MD
Aaron Farberg, MD, discuss how JAK inhibitors have come under scrutiny in the past for systemic adverse effects in oral formulations, while exploring the safety data of topical JAK inhibitors in the pediatric population, which appears to show a more favorable risk profile with localized effects.
Advertisement
This news content has been independently developed and is not endorsed by the American Academy of Dermatology.
Video content above is prompted by the following:
- JAK inhibitors have come under scrutiny in the past for systemic adverse effects in oral formulations. How do you interpret the safety data of topical JAK inhibitors in the pediatric population?
Advertisement
Related to this article

A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.

SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.

Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.

No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.

Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
2
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
3
GLP-1 Candidacy and Prescribing Considerations in Psoriasis
4
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
5







